Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Intellia Therapeutics, Inc., Charles River Laboratories International or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Intellia Therapeutics, Inc., Charles River Laboratories International and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Intellia Therapeutics, Inc., Charles River Laboratories International and Inc.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children’s Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Latest Biotechnology and Intellia Therapeutics, Inc., Charles River Laboratories International, Inc. Stock News

As of September 10, 2026, Intellia Therapeutics, Inc. had a $1.7 billion market capitalization, compared to the Biotechnology median of $272.7 million. Intellia Therapeutics, Inc.’s stock is up 32.7% in 2026, down 6.5% in the previous five trading days and up 0.42% in the past year.

Currently, Intellia Therapeutics, Inc. does not have a price-earnings ratio. Intellia Therapeutics, Inc.’s trailing 12-month revenue is $59.5 million with a -672.2% net profit margin. Year-over-year quarterly sales growth most recently was -45.8%. Analysts expect adjusted earnings to reach $-3.157 per share for the current fiscal year. Intellia Therapeutics, Inc. does not currently pay a dividend.

As of September 10, 2026, Charles River Laboratories International, Inc. had a $13.0 billion market cap, putting it in the 81st percentile of all stocks. Charles River Laboratories International, Inc.’s stock is up 36.9% in 2026, down 6.4% in the previous five trading days and up 73.47% in the past year.

Currently, Charles River Laboratories International, Inc. does not have a price-earnings ratio. Charles River Laboratories International, Inc.’s trailing 12-month revenue is $4.0 billion with a -6.0% net profit margin. Year-over-year quarterly sales growth most recently was -2.7%. Analysts expect adjusted earnings to reach $11.318 per share for the current fiscal year. Charles River Laboratories International, Inc. does not currently pay a dividend.

How We Compare Intellia Therapeutics, Inc., Charles River Laboratories International and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Intellia Therapeutics, Inc., Charles River Laboratories International and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Intellia Therapeutics, Inc., Charles River Laboratories International and Inc. Growth Grades

Company	Ticker	Growth
Intellia Therapeutics, Inc.	NTLA	F
Charles River Laboratories International, Inc.	CRL	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Intellia Therapeutics, Inc. has a Growth Score of 17, which is Very Weak. Charles River Laboratories International, Inc. has a Growth Score of 77, which is Strong.

The Growth Grade Winner: Charles River Laboratories International, Inc.

As you can clearly see from the Growth Grade breakdown above, Charles River Laboratories International, Inc. has a more attractive growth grade than Intellia Therapeutics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Charles River Laboratories International, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Intellia Therapeutics, Inc., Charles River Laboratories International and Inc.’s Quality Grades

Company	Ticker	Quality
Intellia Therapeutics, Inc.	NTLA	D
Charles River Laboratories International, Inc.	CRL	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Intellia Therapeutics, Inc. has a Quality Score of 27, which is Weak. Charles River Laboratories International, Inc. has a Quality Score of 59, which is Average.

The Quality Stock Winner: No Clear Winner

Neither Intellia Therapeutics, Inc., Charles River Laboratories International or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Intellia Therapeutics, Inc., Charles River Laboratories International or Inc. is the better investment when it comes to quality.

Intellia Therapeutics, Inc., Charles River Laboratories International and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Intellia Therapeutics, Inc.	NTLA	D
Charles River Laboratories International, Inc.	CRL	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Intellia Therapeutics, Inc. has a Earnings Estimate Score of 35, which is Negative. Charles River Laboratories International, Inc. has a Earnings Estimate Score of 57, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Intellia Therapeutics, Inc., Charles River Laboratories International or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Intellia Therapeutics, Inc., Charles River Laboratories International or Inc. is the better investment when it comes to estimate revisions.

Other Intellia Therapeutics, Inc., Charles River Laboratories International and Inc. Grades

In addition to Quality, Growth and Estimate Revisions, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Intellia Therapeutics, Inc., Charles River Laboratories International and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Intellia Therapeutics, Inc., Charles River Laboratories International or Inc. Stock?

Overall, Intellia Therapeutics, Inc. stock has a Growth Score of 17, Estimate Revisions Score of 35 and Quality Score of 27.

Charles River Laboratories International, Inc. stock has a Growth Score of 77, Estimate Revisions Score of 57 and Quality Score of 59.

Comparing Intellia Therapeutics, Inc., Charles River Laboratories International and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.